Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Dalton Travis, the President, CEO, and Executive Chair of Claritev Corp (NASDAQ:CTEV), recently acquired 5,252 shares of the company’s Class A common stock. The shares were purchased on March 7 at a weighted average price of $19.197 per share, amounting to a total transaction value of $100,822. This insider purchase comes as InvestingPro data shows the stock has gained over 90% in the past six months, despite being down 49% year-over-year.
The filing indicates that these shares were bought in multiple transactions, with prices ranging from $19.13 to $19.20. Following this acquisition, Travis now directly owns 239,285 shares of Claritev Corp. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission, indicating a direct ownership nature. According to InvestingPro analysis, the company currently appears undervalued, with management actively buying back shares despite operating with significant debt and a high EBIT valuation multiple. For deeper insights into Claritev’s financial health and 10+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Claritev Corp reported a decline in its annual revenue for 2024, totaling $930.6 million, a 3.2% decrease from the previous year. The company also provided guidance for 2025, indicating potential revenue decline or flat growth compared to 2024. Despite this, Claritev has initiated a transformation program aimed at reducing operating costs by 10-15% and focusing on high-growth segments like HST and Data/Decision Science. Piper Sandler raised Claritev’s stock target to $19 from $10, maintaining a Neutral rating, citing the impact of healthcare regulations on revenue prospects. The company announced changes to executive compensation, including severance arrangements and equity grants, as part of its corporate governance adaptation. Additionally, Citi analysts adjusted their outlook on Multiplan, now rebranded as Claritev, raising the stock price target to $21 while maintaining a Neutral rating. This follows the company’s recent fourth-quarter results and fiscal year 2025 guidance, which did not fully meet expectations. Claritev’s strategic initiatives continue as the company navigates challenges and seeks to align executive incentives with shareholder interests.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.